Company intelligence / Profile preview

iTeos Therapeutics

Watertown, Massachusetts, United Statesiteostherapeutics.com ↗

Ownership: Public · ITOS
Employees: ~100
Development stage: Phase 3

Overview

iTeos has multiple clinical programs with promising results. Their GALAXIES Lung-201 trial with belrestotug (EOS-448) + dostarlimab in NSCLC has interim data expected in Q2 2025. The company recently deprioritized inupadenant despite showing a 63.9% overall response rate and 7.7 months median PFS in Phase 2 for NSCLC.

Therapeutic areas: Oncology
Modalities: Antibodies (including IgG1)Small molecules
Industry: Biotech

Drug pipeline

6 assets

inupadenant

5 more assets in the full pipeline.

Request access →

Partnerships

GSK (dostarlimab combination trials)

Beyond the preview

Go deeper on iTeos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iTeos Therapeutics.

Explore the full profile